ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
ASH 2024 – Astra sets the bar for Merck's Curon buy
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
ASH 2024 – J&J aims at a myeloma precursor
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
ASH 2024 – CellCentric's myeloma first
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
